Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 8/20 | 0.50 |
| ▸ | DHODH | Q02127 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TACR2 | P21452 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27729454 | 0.90 | LMNA (0.53) | SMN1; SMN2MEN1KMT2APDE10ATSHR | |
| SCHEMBL2373281 | 0.88 | KDM4E (0.55) | SMN1; SMN2MEN1KMT2ATACR3DHODH | |
| SCHEMBL4668037 | 0.88 | TACR3 (0.53) | SMN1; SMN2MEN1KMT2ATACR3DHODH | |
| SCHEMBL4875432 | 0.87 | KDM4E (0.49) | SMN1; SMN2MEN1KMT2APDE10ATSHR | |
| SCHEMBL14115125 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2MEN1KMT2APDE10ATSHR | |
| SCHEMBL5945389 | 0.86 | PDE10A (0.49) | MEN1KMT2APDE10ATSHRTACR3 | |
| SCHEMBL2372559 | 0.85 | TRPV4 (0.50) | SMN1; SMN2TACR3DHODHTACR2KDM4E | |
| SCHEMBL1581252 | 0.84 | DHODH (0.65) | KMT2APDE10ATSHRTACR3DHODH | |
| SCHEMBL4868977 | 0.84 | MEN1 (0.54) | SMN1; SMN2MEN1KMT2ATACR3LMNA | |
| SCHEMBL6506852 | 0.84 | DHODH (0.56) | SMN1; SMN2MEN1KMT2APDE10ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549872-B1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8658636-B2 | TRPV4 antagonists | GlaxoSmithKline, LLC (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2549872-A1 | TRPV4 ANTAGONISTS | GlaxoSmithKline LLC (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2013-01-10 | — | — | US | disclosed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071621-B2 | Alkylsulphonamide quinolines | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| WO-2011119704-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011119701-A1 | TRPV4 ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| US-20100029717-A1 | Alkylsulphonamide Quinolines | SIMPSON THOMAS | 2010-02-04 | — | — | US | disclosed |
| EP-1334088-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002083645-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002044154-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044165-A1 | QUINOLINE DERIVATIVES AS NK-3 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002038548-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-05-16 | — | — | WO | disclosed |
| WO-2002038547-A1 | QUINOLINE DERIVATIVES AS NK-3 AND NK-2 ANTAGONISTS | GLAXOSMITHKLINE SPA (IT) | 2002-05-16 | — | — | WO | disclosed |
| EP-1131294-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031038-A1 | QUINOLINE DERIVATIVES AS NK-2 AND NK-3 RECEPTOR LIGANDS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029717-A1 | Alkylsulphonamide Quinolines | RECQL, NQO2, QDPR | SMN1; SMN2 2314/4885MEN1 858/4885KMT2A 966/4885 |
| US-20130012499-A1 | TRPV4 ANTAGONISTS | TRPV4, TRPV2, TRPV5 | SMN1; SMN2 4452/4885MEN1 4069/4885KMT2A 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.